LifeTech Scientific Corp
HKEX:1302
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (5.9), the stock would be worth HK$1.99 (8% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.4 | HK$2.16 |
0%
|
| 3-Year Average | 5.9 | HK$1.99 |
-8%
|
| 5-Year Average | 8.8 | HK$2.97 |
+38%
|
| Industry Average | 4.4 | HK$1.49 |
-31%
|
| Country Average | 2.8 | HK$0.94 |
-57%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
HK$8.8B
|
/ |
Jan 2026
¥1.4B
|
= |
|
|
HK$8.8B
|
/ |
Dec 2026
¥1.6B
|
= |
|
|
HK$8.8B
|
/ |
Dec 2027
¥1.8B
|
= |
|
|
HK$8.8B
|
/ |
Dec 2028
¥2.1B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
LifeTech Scientific Corp
HKEX:1302
|
10B HKD | 6.4 | 59 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 16.1 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 3.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 4.8 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 2.9 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 4.1 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7.7 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 1.7 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 10.4 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 1.9 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 5.8 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
LifeTech Scientific Corp
Glance View
LifeTech Scientific Corp. is an investment holding company, which engages in the development, manufacture, research, development and market of minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders. The company is headquartered in Shenzhen, Guangdong and currently employs 943 full-time employees. The company went IPO on 2011-11-10. The firm operates through three business segments. The Congenital Heart Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to congenital and structural heart diseases. The Peripheral Vascular Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to peripheral vascular diseases. The Surgical Vascular Repair Business segment is engaged in the research and development, manufacture and trading of devices related to surgical vascular repair.
